Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

Opinion
Video

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

Related Videos
Carrie L. Kitko, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Lori A. Leslie, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Lori A. Leslie, MD
Changchun Deng, MD, PhD